

**LISA A. JACKSON, MD, MPH**  
**Curriculum Vitae**  
**January 8, 2021**

Senior Investigator, Kaiser Permanente Washington Health Research Institute,  
Kaiser Foundation Health Plan of Washington

**EDUCATION**

American Embassy School (High School), New Delhi, India, 1980  
BS, Biology, College of William and Mary, Williamsburg, Virginia, 1984  
MD, University of Virginia School of Medicine, Charlottesville, Virginia, 1988  
MPH, University of Washington School of Public Health and Community Medicine,  
Seattle, Washington, 1996

**PROFESSIONAL POSITIONS AND TRAINING**

1988-1991 Intern and Resident, Internal Medicine,  
University of Washington Medical Center, Seattle, Washington

1991-1993 Epidemic Intelligence Service Officer  
Meningitis and Special Pathogens Branch, Division of Bacterial and Mycotic Diseases,  
National Center for Infectious Diseases, Centers for Disease Control and Prevention,  
Atlanta, Georgia

1993-1994 Preventive Medicine Resident  
National Center for Infectious Diseases, Centers for Disease Control and  
Prevention, Seattle-King County Dept. of Public Health, Seattle, Washington

1994-1996 Senior Fellow  
Department of Epidemiology, School of Public Health and Community Medicine,  
University of Washington, Seattle, Washington

1996- Research Assistant (1996-2000), Research Associate (2000-2005), and  
Research Professor (2005-2020), Department of Epidemiology, School of Public  
Health, University of Washington, Seattle, Washington

1996- Assistant (1996-2000), Associate (2000-2004), and Senior (2004- ) Scientific  
Investigator, Kaiser Permanente Washington Health Research Institute\*, Seattle,  
Washington

*\*Kaiser Permanente acquired Group Health in February 2017, at which point  
Group Health Research Institute became Kaiser Permanente Washington  
Health Research Institute*

**HONORS AND AWARDS**

Phi Beta Kappa, 1983  
Alpha Omega Alpha, 1986  
James H. Nakano Citation, 1996  
ICAAC Young Investigator Award, 1997

**PROFESSIONAL MEMBERSHIPS**

Fellow, American College of Physicians  
Fellow, American College of Preventive Medicine  
American Epidemiological Society  
American Public Health Association

Fellow, Infectious Diseases Society of America

### BOARD CERTIFICATION

American Board of Internal Medicine, initially certified 1991, recertified 2007, valid through 2017  
 American Board of Public Health and Preventive Medicine, initially certified 1997, valid without expiration

### PUBLICATIONS

#### Manuscripts in Refereed Journals

#### 1993

1. **Jackson LA**, Kaufmann AF, Adams WG, et al. Outbreak of leptospirosis associated with swimming. *Pediatr Infect Dis J* 1993;12:48-54.
2. **Jackson LA**, Wenger JD. Listeriosis—A Foodborne Disease. *Infect Med* 1993;10(2):61-66.
3. **Jackson LA**, Perkins BA, Wenger JD. Cat scratch disease in the United States: an analysis of three national data bases. *Am J Public Health* 1993;83:1707-1711.
4. Smith DK, Neal JJ, Holmberg SD and the Centers for Disease Control Idiopathic CD4+ T-Lymphocytopenia Task Force. Unexplained opportunistic infections and CD4 T-lymphocytopenia without HIV infection: an investigation of cases in the United States. *N Engl J Med* 1993;328:373-379.

#### 1994

5. **Jackson LA**, Tenover FC, Baker C, et al. Prevalence of *Neisseria meningitidis* relatively resistant to penicillin in the United States, 1991. *J Infect Dis* 1994;169:438-441.
6. Wenger JD, **Jackson LA**, Raj P, Tonelli MJ. Issues in the control of outbreaks of group C meningococcal disease in the United States. *Infect Dis Clin Practice* 1994;3:136-140.

#### 1995

7. **Jackson LA**, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States: an emerging threat. *JAMA* 1995;273:383-389.
8. **Jackson LA**, Schuchat A, Gorsky RD, Wenger JD. Should college students be vaccinated against meningococcal disease? A cost-benefit analysis. *Am J Public Health* 1995;85:843-845.
9. **Jackson LA**, Hilsdon R, Farley MM, et al. Risk factors for adult group B streptococcal disease. *Ann Intern Med* 1995;123:415-420.
10. Kuo C-C, **Jackson LA**, Campbell LA, Grayston JT. Chlamydia pneumoniae (TWAR). *Clin Microbiol Rev* 1995;8:451-461.
11. Imrey PB, **Jackson LA**, Ludwinski PH, et al. Meningococcal carriage, alcohol consumption, and campus bar patronage in a serogroup C meningococcal disease outbreak. *J Clin Microbiol* 1995;33:3133-3137.

#### 1996

12. Imrey PB, **Jackson LA**, Ludwinski PH, et al. An outbreak of serogroup C meningococcal disease associated with campus bar patronage. *Am J Epidemiol* 1996;143:624-630.
13. **Jackson LA**, Spach DH, Kippen DA, et al. Seroprevalence to *Bartonella quintana* among patients at a community clinic in downtown Seattle. *J Infect Dis* 1996;173:1023-6.
14. **Jackson LA**, Spach DH. Emergence of *Bartonella quintana* infection among homeless persons. *Emerg Infect Dis* 1996;2:141-143.
15. **Jackson LA**, Stewart LK, Solomon SL, et al. Risk of infection with hepatitis A, B, or C, cytomegalovirus, measles, and varicella among child care providers. *Pediatr Infect Dis J* 1996;15:584-9.

16. Kuo C-C, **Jackson LA**, Lee A, Grayston JT. *In vitro* Activities of Azithromycin, Clarithromycin, and Other Antibiotics Against *C. pneumoniae*. *Antimicrobial Agents Chemother* 1996;40:2669-70.
17. **Jackson LA**, Alexander ER, DeBolt C, et al. Evaluation of the use of mass chemoprophylaxis during a school outbreak of ET-5 serogroup B meningococcal disease. *Pediatr Infect Dis J* 1996;15:992-8.

**1997**

18. **Jackson LA**, Campbell LA, Schmidt RA, et al. Frequency of detection of *Chlamydia pneumoniae* in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. *Am J Pathol* 1997;150:1785-90.
19. **Jackson LA**, Campbell LA, Kuo C-C, Rodriguez DI, Grayston JT. Isolation of *Chlamydia pneumoniae* from a carotid endarterectomy specimen. *J Infect Dis* 1997;176:292-5.
20. Grayston JT, Kuo C-C, Campbell LA, Wang S-P, **Jackson LA**. *Chlamydia pneumoniae* and cardiovascular disease. *Cardiologia* 1997;42:1145-1151.
21. Pearson DC, **Jackson LA**, Wagener B, Foss E. Improving influenza immunization rates in a managed care setting. *J Clin Outcomes Management* 1997;4:29-30.
22. Cordell RL, MacDonald JK, Solomon SL, **Jackson LA**, Boase J. Illnesses and absence due to illness among children attending child care facilities in Seattle-King County, Washington. *Pediatrics* 1997;100:850-5.

**1998**

23. Pearson DC, **Jackson LA**, Wagener B, Sarver L. A comprehensive influenza campaign in a managed care setting. *Vaccine* 1998;16:1718-21.
24. Smith WJ, **Jackson LA**, Watts DH, Koepsell TD. Prevention of chickenpox in reproductive-age women: cost-effectiveness of routine prenatal screening with postpartum vaccination of susceptibles. *Obstet Gynecol* 1998 Oct;92:535-45.

**1999**

25. **Jackson LA**, Benson P, Sneller V-P, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. *JAMA* 1999;281:243-8.
26. **Jackson LA**, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM. Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, or doxycycline. *Emerg Infect Dis* 1999;5:281-284.
27. **Jackson LA**, Holmes SJ, Mendelman PM, et al. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. *Vaccine* 1999;17:1905-9.
28. Nichol KL, Mendelman PM, Mallon K, **Jackson LA**, Gorse GJ, Belshe RB, Glezen WP, Wittes J, for the Intranasal Influenza Virus Vaccine in Healthy Adults Trial Group. The effectiveness of live attenuated intranasal influenza virus vaccine in reducing illness, absenteeism, and health care resource use among healthy, working adults in a year when a drifted influenza A virus predominated. *JAMA* 1999;282:137-144.
29. Pearson D, **Jackson LA**, Winkler B, Foss B, Wagener B. Use of automated pharmacy systems and other patient data registries to identify and recruit enrollees for an influenza campaign. *Eff Clin Pract* 1999;2:17-22.
30. **Jackson LA**, Stewart DK, Wang SP, Cantrell T, Cooke DB, Grayston JT. Safety and effect on anti-*Chlamydia pneumoniae* antibody titers of a one-month course of daily azithromycin among adults with coronary artery disease. *J Antimicrob Chemother* 1999;44:411-414.
31. Grayston JT, **Jackson LA**, Kennedy WJ, Kronmal RA. Secondary prevention trials for coronary artery disease with antibiotic treatment for *Chlamydia pneumoniae* – design issues. *Am Heart J* 1999;138:545-549.

**2000**

32. Vincent JM, Cherry JD, Nauschwetz WF, Lipton A, Ono CM, Costello CM, Sakaguchi LK, Hsue G, **Jackson LA**, Tachdjian R, Cotter PA, Gornbein JA. Prolonged afebrile non-productive cough illnesses in American soldiers in Korea: A serologic search for causation. *Clin Infect Dis* 2000;30:534-9.
33. **Jackson LA**. Description and status of ACES. *J Infect Dis* 2000;181(Suppl 3):S579-81.
34. **Jackson LA**, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM. Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, or doxycycline. *J Infect Dis* 2000;181(Suppl 3):S563-5.
35. **Jackson LA**, Campbell LA, Schmidt RA, et al. Frequency of detection of *Chlamydia pneumoniae* in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. *J Infect Dis* 2000;181(Suppl 3):S447-8.
36. Pellissier JM, Coplan PM, **Jackson LA**, May J. The effect of additional shots on the vaccine administration process: Results of a time-motion study in two settings. *Am J Managed Care* 2000;6:1038-44.
37. **Jackson LA**, Wang SP, Grayston JT, Cherry JD. The frequency of serologic evidence of *Bordetella* infections and mixed infections with other respiratory pathogens in University students with cough illnesses. *Clin Infect Dis* 2000; 31(1):3-6.
38. **Jackson LA**, Keene WE, Diermayer M, et al. Where's the beef? The role of cross-contamination in four chain restaurant-associated outbreaks of *Escherichia coli* O157:H7 in the Pacific Northwest. *Arch Intern Med* 2000; 160(15):2380-2385.
39. **Jackson LA**, Wang SP, Nazar-Stewart V, Grayston JT, Vaughan TL. Association of *Chlamydia pneumoniae* immunoglobulin A seropositivity and risk of lung cancer. *Cancer Epidemiol Biomarkers Prevention* 2000;9:1263-1266.

#### 2001

40. **Jackson LA**, Falls S, Yu O, George J, Pietrobon PJ, Rubanowice D, Froeschle J. Diphtheria antitoxin levels among children primed with a lot of DTaP vaccine with a subpotent diphtheria toxoid component. *J Infect Dis* 2001;183:1698-1700.
41. Dowell SF, Peeling RW, Boman J, Carlone GM, Fields BS, Guarner J, Hammerschlag MR, **Jackson LA**, Kuo C-C, Maass M, Messmer TO, Talkington D, Tondella ML, Zaki SR, and the *C. pneumoniae* workshop participants. Standardizing *Chlamydia pneumoniae* Assays: Recommendations from the Centers for Disease Control and Prevention (USA), and the Laboratory Centre for Disease Control (Canada). *Clin Infect Dis* 2001;33:492-503.
42. **Jackson LA**, Austin G, Chen RT, et al and the Vaccine Safety Datalink Study Group. Safety and immunogenicity of varying doses of trivalent inactivated influenza vaccine administered by needle-free jet injectors. *Vaccine* 2001;19:4703-9.

#### 2002

43. DeStefano F, Gu D, Kramarz P, Truman BI, Iademarco MF, Mullooly JP, **Jackson LA**, Davis RL, Black SB, Shinefield HR, Marcy SM, Ward JI, Chen RT, and the Vaccine Safety Datalink Research Group. Childhood vaccinations and risk of asthma. *Pediatric Infectious Disease J* 2002;21:498-504.
44. **Jackson LA**, Carste B, Malais D, Froeschle J. Retrospective population-based assessment of medically attended injection site reactions, seizures, allergic responses and febrile episodes after acellular pertussis vaccine combined with diphtheria and tetanus toxoids. *Pediatric Infect Dis J* 2002;21:781-5.
45. **Jackson LA**, Yu O, Heckbert SR, Psaty BM, Malais D, Barlow WE, Thompson WW. Influenza vaccination is not associated with a reduction in the risk of recurrent coronary events. *Am J Epi* 2002;156:634-640.

#### 2003

46. **Jackson LA**, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. *N Engl J Med* 2003;348:1747-55.

47. DeStefano F, Verstraeten T, **Jackson LA**, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. *Arch Neurology* 2003;60:504-509.
48. Littman AJ, Thornquist MD, **Jackson LA**, White E, Goodman GE, Vaughan TL. Previous lung disease and risk of lung cancer in a large prospective cohort study. *Ann Epidemiol* 2003 Sep;13(8):563-4.
49. Bohlke K, Galil K, **Jackson LA**, Schmid DS, Starkovich P, Loparev VN, Seward JF. Postpartum varicella vaccination: is the vaccine virus excreted in breast milk? *Obstet Gynecol* 2003;102:970-7.

#### 2004

50. Littman AJ, **Jackson LA**, White E, Thornquist MD, Gaydos CA, Vaughan TL. Interlaboratory reliability of Chlamydia pneumoniae immunoglobulin A and G antibody titers using the microimmunofluorescence test. *Clin Diagn Lab Immunol* 2004 May;11(3):615-7.
51. Littman AJ, Thornquist MD, White E, **Jackson LA**, Goodman GE, Vaughan TL. Prior lung disease and risk of lung cancer in a large prospective study. *Cancer Causes and Control* 2004;15:819-827.
52. Littman AJ, White E, **Jackson LA**, Thornquist MD, Gaydos CA, Goodman GE, Vaughan TL. Chlamydia pneumoniae infection and risk of lung cancer. *Cancer Epidemiol Biomarkers Prevention* 2004;13:1624-30.
53. France EK, Glanz JM, Xu S, Davis RL, Black SB, Shinefield HR, Zangwill KM, Marcy SM, Mullooly JP, **Jackson LA** and the Vaccine Safety Datalink Team. Safety of the trivalent inactivated influenza vaccine among children: a population-based study. *Arch Pediatr Adolesc Med* 2004;158:1031-6.
54. Jackson ML, Neuzil KM, Thompson WW, Shay DK, Yu O, Hanson CA, **Jackson LA**. The burden of community-acquired pneumonia in seniors: results of a population-based study. *Clin Infect Dis* 2004;39:1642-50.

#### 2005

55. Grayston JT, Kronmal RA, **Jackson LA**, et al. Antibiotic treatment for secondary prevention of coronary events: results of the Azithromycin and Coronary Events Study (ACES). *N Engl J Med* 2005;352:1637-45.
56. **Jackson LA**, Benson P, Neuzil KM, Grandjean M, Marino JL. Burden of community-onset Escherichia coli bacteremia in seniors. *J Infect Dis* 2005;191:1523-1529.
57. **Jackson LA**, Neuzil KM, Whitney CG, et al. Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. *Vaccine* 2005;23:3697-3703.
58. Littman AJ, **Jackson LA**, Vaughan TL. Chlamydia pneumoniae and lung cancer: epidemiologic evidence. *Cancer Epidemiol Biomarkers Prevention* 2005;14(4):773-8.
59. Jumaan A, Yu O, **Jackson LA**, Bohlke K, Galil K, Seward J. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. *J Infect Dis* 2005;191:2002-7.

#### 2006

60. **Jackson LA**, Nelson JC, Whitney CG, et al. Assessment of the safety of a third dose of pneumococcal polysaccharide vaccination in the Vaccine Safety Datalink population. *Vaccine* 2006;24:151-6.
61. Chi RC, **Jackson LA**, Neuzil KM. Characteristics and outcomes of older adults with community-acquired pneumococcal bacteremia. *J Am Geriatr Soc* 2006;54:115-120.
62. **Jackson LA**, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. *Int J Epidemiol* 2006;35:337-344.
63. **Jackson LA**, Nelson JC, Benson P, et al. Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. *Int J Epidemiol* 2006;35:345-352.

64. **Jackson LA**, Dunstan M, Starkovich P, et al. Prophylaxis with acetaminophen or ibuprofen prior to the fifth DTaP vaccination: A randomized, controlled trial. *Pediatrics* 2006;117:620-5.
65. Lindsay L, **Jackson LA**, Savitz DA, Weber DJ, Koch GG, Kong L, Guess HA. Community influenza activity and risk of acute influenza-like illness episodes among healthy unvaccinated pregnant and postpartum women. *Am J Epidemiol* 2006;163:838-848.
66. Heffelfinger JD, Heckbert SR, Psaty BM, Weiss NS, Thompson WW, Bridges CB, **Jackson LA**. Influenza vaccination and risk of incident myocardial infarction. *Human Vaccines* 2006;2:161-6.
67. Neuzil KM, **Jackson LA**, Nelson J, et al. Immunogenicity and reactogenicity of one vs two doses of trivalent inactivated influenza vaccine in vaccine-naïve 5-8-year-old children. *J Infect Dis* 2006;194:1032-9.
68. Hambidge SJ, Glanz JM, France EK, McClure D, Xu S, Yamasaki K, **Jackson L**, et al. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. *JAMA* 2006;296:1990-1997.
69. **Jackson LA**, Neuzil KM, Baggs J, et al. Compliance with the recommendations for two doses of trivalent inactivated influenza vaccine in children less than nine years of age receiving influenza vaccine for the first time: a Vaccine Safety Datalink study. *Pediatrics* 2006;118:2032-7.
70. France EK, Smith-Ray R, McClure D, Hambidge S, Xu S, Yamasaki K, Shay D, Weintraub E, Fry AM, Black S, Shinefield H, Mullooly J, **Jackson LA**. Impact of influenza vaccination during pregnancy on the incidence of acute respiratory illness visits among infants. *Arch Pediatr Adolescent Med* 2006;160:1277-83.

## 2007

71. Mullooly JP, Bridges CB, Thompson WW, Chen J, Weintraub E, **Jackson LA**, Black S, Shay DK. Influenza- and RSV-associated hospitalizations among adults. *Vaccine* 2007;25:846-55.
72. Yu O, Bohlke K, Hanson CA, Delaney K, Rees T, Zavitkovsky A, Ray P, Mullooly J, Black SB, Benson P, Thompson WW, Davis RL, **Jackson LA**. Hepatitis B vaccine and risk of autoimmune thyroid disease: a Vaccine Safety Datalink study. *Pharmacoepi and Drug Safety* 2007;16:736-45.
73. Glazer NL, Dublin S, Smith NL, French B, **Jackson LA**, Hrachovec J, Siscovick DS, Psaty BM, Heckbert SR. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. *Arch Intern Med* 2007;167:246-52.
74. Jackson ML, Nelson JC, Chen RT, Davis RL, **Jackson LA** for the Vaccine Safety Datalink Investigators. Vaccines and changes in coagulation parameters in adults on chronic warfarin therapy: a cohort study. *Pharmacoepi and Drug Safety* 2007;16:790-796.
75. **Jackson LA**, Neuzil KM, Nahm M, et al. Immunogenicity of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. *Vaccine* 2007;25:4029-37.
76. Simonsen L, Taylor R, Goodwin K, Viboud C, Miller MA, **Jackson LA**. Influenza vaccination and influenza mortality among the elderly. *Lancet Infect Disease* 2007;7:658-66.
77. Thompson WW, Price C, Goodson B, Shay D, Benson P, Hinrichsen V, Lewis E, Eriksen E, Ray P, Ross P, Marcy SM, Dunn J, **Jackson LA**, Lieu T, Black S, Stewart G, Weintraub ES, Davis RL, Destefano F for the Vaccine Safety Datalink Team. Early life exposure to thimerosal and neurodevelopmental functioning at seven to ten years of age. *N Engl J Med* 2007;357:1281-92.

## 2008

78. **Jackson LA**, Starkovich P, Dunstan M, et al. A prospective assessment of the effect of needle length and injection site on the risk of local reactions to the 5th DTaP vaccination. *Pediatrics* 2008;121:e646-e652.
79. France EK, Glanz J, Xu S, Hambidge S, Yamasaki K, Black SB, Marcy M, Mullooly JP, **Jackson LA**, Nordin J, Belongia EA, Lieu T, Chen R, Davis R for the Vaccine Safety

- Datalink Team. The risk of immune thrombocytopenic purpura following measles-mumps-rubella immunization in children. *Pediatrics* 2008;121:e687-e692.
80. Benson PJ, **Jackson LA**, Rees TR, Dunn JB. Changes in DT vaccine frequency and indications for use following introduction of DTaP vaccine. *Human Vaccines* 2008;4:234-7.
  81. **Jackson LA**, Reynolds MA, Harpaz R. Herpes zoster hospitalizations in older adults: causes and validated rates. *Clin Infect Dis* 2008;47:754-9.
  82. Jackson ML, Nelson JC, Weiss NS, Neuzil KM, Barlow W, **Jackson LA**. Influenza vaccination and the risk of community-acquired pneumonia in immunocompetent seniors: results of a population-based case-control study. *Lancet* 2008;372:398-405
  83. Nelson JC, Whitney CG, Yu O, Jackson ML, Scott T, Bounds L, Zavitkovsky A, **Jackson LA**. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. *Vaccine* 2008;26:4947-54.
  84. **Jackson LA**, Janoff EN. Pneumococcal vaccination of seniors: new paradigms for protection. *Clin Infect Dis* 2008;47:1328-38.
- 2009**
85. Jackson ML, Nelson JC, **Jackson LA**. Risk factors for community-acquired pneumonia in immunocompetent seniors. *J Am Geriatr Soc* 2009;57:882-8.
  86. **Jackson LA**, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. *Pediatr Infect Dis J* 2009;28:86-91.
  87. **Jackson LA**, Baxter R, Naleway AL, Belongia EA, Baggs J. Patterns of pneumococcal vaccination and revaccination in elderly and non-elderly adults: a Vaccine Safety Datalink study. *BMC Infect Dis* 2009;9:37.
  88. Nelson JL, Jackson ML, Weiss NS, **Jackson LA**. New strategies are needed to improve the accuracy of influenza vaccine effectiveness estimates among seniors. *J Clin Epidemiol* 2009;62:687-94.
  89. Harris K, Baggs J, Davis RL, Black S, **Jackson LA**, Mullooly JP, Chapman LE. Influenza vaccination coverage among adult solid organ transplant recipients at three health maintenance organizations, 1995-2005. *Vaccine* 2009;27:2335-41.
  90. **Jackson LA**, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, Dull PM and V59P13 study group. A Phase III, head-to-head comparison of an investigational quadrivalent meningococcal conjugate vaccine, MenACWY-CRM, with the licensed meningococcal ACWY conjugate vaccine, in adolescents. *Clin Infect Dis* 2009;49:e1-10.
  91. Nelson JC, Bittner RC, Bounds L, Zhao S, Baggs J, Donahue JG, Hambidge SJ, Jacobsen SJ, Klein NP, Naleway AL, Zangwill KM, **Jackson LA**. Compliance with multiple dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. *Am J Public Health* 2009;99:S389-97.
  92. Dublin S, Jackson ML, Nelson JC, Weiss NS, Larson E, **Jackson LA**. Statin use and risk of community-acquired pneumonia in the elderly: results of a population-based case-control study. *BMJ* 2009;338:b2137.
  93. **Jackson LA**, Yu O, Nelson J, Belongia EA, Hambidge SJ, Baxter R, Naleway A, Gay C, Nordin J, Baggs J, Iskander J. Risk of medically-attended local reactions following diphtheria toxoid containing vaccines in adolescents and young adults: a Vaccine Safety Datalink Study. *Vaccine* 2009;27:4912-6.
  94. **Jackson LA**, Yu O, Belongia EA, Hambidge SJ, Nelson J, Baxter R, Naleway A, Gay C, Nordin J, Baggs J, Iskander J. Frequency of medically attended adverse events following tetanus and diphtheria toxoid vaccine in adolescents and young adults: a Vaccine Safety Datalink Study. *BMC Infect Dis* 2009;9:165.
  95. Simonsen L, Viboud C, Taylor RJ, Miller MA, **Jackson L**. Influenza vaccination and mortality benefits: new insights, new opportunities. *Vaccine* 2009;27:6300-4.

96. National Vaccine Advisory Committee. Financing vaccination of children and adolescents: National Vaccine Advisory Committee recommendations. *Pediatrics* 2009;124:S558-62.
97. Naleway AL, Belongia EA, Donahue JG, Kieke BA, Glanz JM, Vaccine Safety Datalink. Risk of immune hemolytic anemia in children following immunization. *Vaccine* 2009;27:7394-7.

**2010**

98. Belongia EA, Irving SA, Shui IM, Kulldorff M, Lewis E, Yin R, Lieu TA, Weintraub E, Yih WK, Li R, Baggs J; Vaccine Safety Datalink Investigation Group. Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. *Pediatr Infect Dis J* 2010;29:1-5.
99. **Jackson LA**, Gaglani MJ, Keyserling HL, Balsler J, Bouveret N, Fries L, Treanor JJ. Safety and efficacy of an inactivated influenza vaccine in adults: a randomized, placebo-controlled trial over two influenza seasons. *BMC Infect Dis* 2010;10:71.
100. Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, **Jackson LA**. Use of proton pump inhibitors and histamine-type 2 receptor blockers and risk of pneumonia in older adults: a population-based case-control study. *Pharmacoepi Drug Safety* 2010;19:792-802.
101. High KP, D'Aquila RT, Fuldner RA, Gerding DN, Halter JB, Haynes L, Hazzard WR, **Jackson LA**, et al. Workshop on immunizations in older adults: identifying future research agendas. *J Am Geriatr Soc* 2010;58:765-776.
102. Metersky ML, Dransfield MT, **Jackson LA**. Determining the optimal pneumococcal vaccination strategy for adults: Is there a role for the pneumococcal conjugate vaccine? *Chest* 2010;138:486-90.
103. Prevots DR, Shaw PA, Strickland D, **Jackson L**, Raebel MA, Blosky MA, Montes de Oca R, Shea YR, Seitz AE, Holland SM, Olivier KN. Nontuberculous mycobacterial lung disease prevalence, four integrated healthcare delivery systems. *Am J Resp Crit Care Med* 2010;182:970-6.
104. Weycker D, Strutton D, Edelsberg J, Sata R, **Jackson LA**. Clinical and economic burden of pneumococcal disease in older US adults. *Vaccine* 2010;28:4955-60.
105. Huang WT, Gargiullo PM, Broder KR, Weintraub ES, Iskander JK, Klein NP, Baggs JM, Vaccine Safety Datalink Team. Lack of association between acellular pertussis vaccine and seizures in early childhood. *Pediatrics* 2010;126:263-9.

**2011**

106. Yu O, Nelson JC, Bounds L, **Jackson LA**. Classification algorithms to improve the accuracy of identifying patients hospitalized with community acquired pneumonia using administrative data. *Epidemiol Infect* 2011;139:1296-1306. doi:10.1017/S0950268810002529
107. Belshe RB, Frey SE, Graham I, Mulligan MJ, Edupaganti S, **Jackson LA**, Wald A, Poland G, Jacobsen R, Heyserling HL, Spearman P, Hill H, Wolff M. Safety and immunogenicity of influenza A H5 subunit vaccines in adults: effect of vaccine schedule and antigenic variant. *J Infect Dis* 2011;203:666-673.
108. **Jackson LA**, Yu O, Nelson JC, Dominguez C, Peterson D, Baxter R, Hambidge SJ, Naleway AL, Belongia EA, Nordin JD, Baggs J. Injection site and risk of medically attended local reactions to the 5<sup>th</sup> DTaP vaccine. *Pediatrics* 2011;127:e581-7.
109. Baggs J, Gee J, Lewis E, Fowler G, Benson P, Lieu T, Naleway A, Klein NP, Baxter R, Belongia E, Glanz J, Hambidge SJ, Jacobsen SJ, **Jackson L**, Nordin J, Weintraub E. The Vaccine Safety Datalink: a Model for Monitoring Immunization Safety. *Pediatrics* 2011;127:S45-S53.
110. Jackson ML, Nelson JC, **Jackson LA**. Why do covariates defined by International Classification of Diseases (ICD) codes fail to remove confounding in pharmacoepidemiologic studies among seniors? *Pharmacoepidemiol Drug Safety* 2011;20:858-865. doi: 10.1002/pds.2160.

111. **Jackson LA**, Peterson D, Dunn J, et al. A randomized placebo-controlled trial of acetaminophen for prevention of post-vaccination fever in infants. *PLoS ONE* 2011;6:e20102. doi:10.1371/journal.pone.0020102.
112. **Jackson LA**, Patel SM, Swamy GK, et al. Immunogenicity of an inactivated monovalent 2009 influenza A (H1N1) vaccine in pregnant women. *J Infect Dis* 2011;204 (6): 854-863. doi: 10.1093/infdis/jir440.
113. Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Von Korff M, **Jackson LA**. Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case control study. *J Amer Geriatrics Assoc* 2011;59:1899-907.
- 2012**
114. Tseng HF, Liu A, Sy L, Marcy SM, Fireman B, Weintraub E, Baggs J, Weinmann S, Baxter R, Nordin J, Daley MF, **Jackson L**, Jacobsen SJ; for the Vaccine Safety Datalink (VSD) Team. Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. *J Intern Med* 2012;271:510-520.
115. Nelson JC, Cook AJ, Yu O, Zhao S, **Jackson LA**, Psaty BM. Methods for observational post-licensure medical product safety surveillance. *Statistical Methods Med Research* 2011. Epub ahead of print.
116. Nelson JC, Yu O, Dominguez C, Cook AJ, Peterson D, Greene SK, Yih K, Daley MF, Jacobsen SJ, Klein NP, Weintraub E, **Jackson LA**. Challenges in the design and analysis of sequentially-monitored postmarket safety surveillance evaluations using electronic observational health care data. *Pharmacoepi Drug Safety* 2012;21 suppl 1:62-71.
117. Hambidge SJ, Ross C, Glanz J, McClure D, Daley MF, Xu S, Shoup JA, Narwaney K, Baggs J, Weintraub E and the Vaccine Safety Datalink Team. Trivalent inactivated influenza vaccine is not associated with sickle cell crises in children. *Pediatrics* 2012;129:e54-9.
118. Klein NP, Lewis E, Baxter R, Weintraub E, Glanz J, Naleway A, **Jackson LA**, Nordin J, Lieu T, Belongia EA, Fireman B. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. *Pediatrics* 2012;129:1-6.
119. Tse A, Tsent H-F, Greene SK, Vellozzi C, Lee GM on behalf of the VSD Rapid Cycle Analysis Influenza Working Group. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. *Vaccine* 2012;30:2024-31.
120. **Jackson LA**, Chen WH, Stapleton JT, et al. Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and seniors. *J Infect Dis* 2012;206:811-20.
121. Chen WH, Winokur PL, Edwards KM, **Jackson LA**, Wald A, Walter EB, Noah DL, Wolff M, Kotloff KL on behalf of the Pandemic H1N1 Vaccine Adult Study Group. Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. *Vaccine* 2012;30:4240-8.
122. Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, **Jackson LA**. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged  $\geq 50$  years. *Vaccine* 2012;30:5437-44.
123. Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, **Jackson LA**. Angiotensin-converting enzyme inhibitor use and pneumonia risk in community-dwelling older adults: results from a population-based case-control study. *Pharmacoepidemiol Drug Saf* 2012;21:1173-82.
124. Zhao S, Cook A, **Jackson L**, Nelson J. Statistical performance of group sequential methods for observational post-licensure medical product safety surveillance: a simulation study. *Stat Interface* 2012;5:381-390.
125. Dirac MA, Horan KL, Doody DR, Meschke JS, Park DR, **Jackson LA**, Weiss NS, Winthrop KL, Cangelosi GA. Environment or host? A case-control study of risk factors for

*Mycobacterium avium* complex lung disease. *Amer J Respir Crit Care Med* 2012;186:684-91.

### 2013

126. Jacobson RM, **Jackson LA**, Reisinger K, Izu A, Odrliin T, Dull PM. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents. *Pediatr Infect Dis J* 2013;32:e170-7.
127. Nelson JC, March T, Lumley T, Larson EB, **Jackson LA**, Jackson M. Validation sampling can reduce bias in healthcare database studies: an illustration using influenza vaccination effectiveness. *J Clin Epidemiol* 2013;66:S110-21.
128. Irving SA, Kieke BA, Donahue JG, Mascola MA, Baggs J, DeStefano F, Cheetham TC, **Jackson LA**, Naleway AL, Glanz JM, Nordin JD, Belongia EA. Trivalent inactivated influenza vaccine and spontaneous abortion. *Obstet Gynecol* 2013;121:159-165.
129. **Jackson LA**, Peterson D, Nelson JC, et al. Vaccination site and risk of local reactions in children 1 through 6 years of age. *Pediatrics* 2013;131:283-9.
130. Nelson JC, Yu O, Dominguez C, Cook AJ, Peterson D, Greene SK, Yih K, Daley MF, Jacobsen SJ, Klein NP, Weintraub E, **Jackson LA**. Adapting group sequential methods to observational postlicensure vaccine safety surveillance: results of a pentavalent combination DTaP-IPV-Hib vaccine safety study. *Am J Epidemiol* 2013;177:131-41.
131. Tseng HF, Sy LS, Qian L, March SM, **Jackson LA**, Glanz J, Nordin J, Baxter R, Naleway A, Donahue J, Weintraub W, Jacobsen SJ, for the Vaccine Safety Datalink Team. Safety of a tetanus-diphtheria-acellular pertussis vaccine when used off-label in an elderly population. *Clin Infect Dis* 2013;56:315-21.
132. Jackson ML, Yu O, Nelson JC, Naleway A, Belongia E, Baxter R, Narwaney K, Jacobsen SJ, Shay DK, **Jackson LA**. Further evidence of bias in observational studies of influenza vaccine effectiveness: the 2009 influenza A (H1N1) pandemic. *Am J Epidemiol* 2013;178:1327-36.
133. **Jackson LA**, Gurtman A, Rice K, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. *Vaccine* 2013;31:3585-93.
134. **Jackson LA**, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults. *Vaccine* 2013;31:3577-84.
135. **Jackson LA**, Gurtman A, van Cleeff M, Frenck R, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. *Vaccine* 2013;31:3594-602.
136. Rowhani-Rahbar A, Fireman B, Lewis E, Nordin J, Naleway A, Jacobsen SJ, **Jackson LA**, Tse A, Belongia EA, Hambidge SJ, Weintraub E, Baxter R, Klein NP. Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in children. *JAMA Pediatr* 2013;167:1111-7.
137. Nelson JC, Shortreed SM, Yu O, Peterson D, Baxter R, Fireman B, Lewis N, McClure D, Weintraub E, Xu S, **Jackson LA**. Integrating database knowledge and epidemiological design to improve the implementation of data mining methods to evaluate vaccine safety in large healthcare databases. *Stat Analysis Data Mining* 2013.

### 2014

138. Weintraub ES, Baggs J, Duffy J, Vellozzi C, Belongia EA, Irving S, Klein NP, Glanz JM, Jacobsen SJ, Naleway A, **Jackson LA**, DeStefano F. Risk of intussusception after monovalent rotavirus vaccination. *N Engl J Med* 2014;370:513-9.
139. Ohmit SE, Thompson MG, Petrie JG, Thaker SN, Jackson ML, Belongia EA, Zimmerman RK, Gaglani M, Lamerato L, Spencer SM, **Jackson L**, Meece JK, Nowalk MP,

- Song J, Zervos M, Cheng P, Rinaldo CR, Clipper L, Shay DK, Piedra P, Monto AS. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. *Clin Infect Dis* 2014;58:319-27.
140. Munoz FM, Bond NH, Maccato M, Pinell P, Hammill HA, Swamy GK, Walter EB, **Jackson LA**, Englund JA, Edwards MS, Healy CM, Petrie CR, Ferreira J, Goll JB, Baker CJ. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. *JAMA* 2014;311:1760-9.
141. Cook AJ, Wellman RD, Nelson JC, **Jackson LA**, Tiwari RC. Group sequential method for observational data by using general estimating equations: application to Vaccine Safety Datalink. *J R Stat Soc* 2014. Epub ahead of print.
142. Havers F, Thaker S, Clippard JR, et al. Use of influenza antiviral agents by ambulatory care clinicians during the 2012-2013 influenza season. *Clinical Infect Dis* 2014;59:774-82.
143. Bernstein DI, **Jackson L**, Patel SM, El Sahly HM, Spearman P, Roupheal N, Rudge TL, Hill H, Goll JB. Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults. *Vaccine* 2014;32:6284-93.
144. McNeil M, Gee J, Weintraub ES, Belongia EA, Lee GM, Glanz JM, Nordin JD, Klein NP, Baxter R, Naleway AL, **Jackson LA**, Omer S, Jacobsen SJ, DeStefano F. The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety. *Vaccine* 2014;32:5390-98.
145. Belshe RB, Frey SE, Graham IL, Anderson EL, **Jackson LA**, et al. Assessment of the immunogenicity of an avian influenza A/An/05 H5N1 vaccine with MF59 adjuvant: a randomized clinical trial in previously H5 vaccinated and unvaccinated persons. *JAMA* 2014;312:1420-8.
146. Callahan ST, Wolff M, Hill HR, Edwards KM, NIAID Vaccine and Treatment Evaluation Unit (VTEU) Pandemic H1N1 Vaccine Study Group. Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults. *J Infect Dis* 2014;210:1270-4.
147. Chen WH, **Jackson LA**, Edwards KM, Keitel WA, Hill H, Noah DL, Creech CB, Patel SM, Mangal B, Kotloff KL. Safety, reactogenicity, and immunogenicity of inactivated monovalent influenza A/H5N1 virus vaccine administered with or without AS03 adjuvant. *Open Forum Infect Dis* 2014;1. doi: 10.1093/ofid/ofu091
- 2015**
148. Jackson ML, Peterson D, Nelson JC, Greene SK, Jacobsen SJ, Belongia EA, Baxter R, **Jackson LA**. Using winter 2009-2010 to assess the accuracy of methods which estimate influenza-related morbidity and mortality. *Epidemiology Infect* 2015;143:2399-407.
149. Keitel WA, **Jackson LA**, Edupuganti S, Winokur P, Mulligan MJ, Lai L, Bellamy AR, Hill H, and the H3N2v Working Group. Safety and immunogenicity of a subvirion monovalent unadjuvanted inactivated influenza A/H3N2 variant (H3N2v) vaccine in healthy persons ≥ 18 years old. *J Infect Dis* 2015;212:552-6.
150. Havers F, Flannery B, Clippard JR, Gaglani M, Zimmerman RK, **Jackson LA**, et al. Use of influenza antiviral medications among outpatients at high risk for influenza-associated complications during the 2013-2014 influenza season. *Clin Infect Dis* 2015;60:1677-80.
151. Stratton KG, Cook AJ, **Jackson LA**, Nelson JC. Simulation study comparing exposure matching with regression adjustment in an observational vaccine safety setting with group sequential monitoring. *Stat Med* 2015;34:1117-33.
152. McLean HQ, Thompson MG, Sundaram ME, Kieke VA, Gaglani M, Murthy K, Piedra PA, Zimmerman RK, Nowalk MP, Raviotta JM, Jackson ML, **Jackson L**, Ohmit SE, Petrie JG, Monto AS, Meece JK, Thaker SN, Clippard JR, Spencer SM, Fry AM, Belongia EA.

- Influenza vaccine effectiveness in the United States during 2012-13: variable protection by age and virus type. *J Infect Dis* 2015;211:1529-40.
153. **Jackson LA**, Campbell JD, Frey SE, et al. Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trial. *JAMA* 2015;314:237-246.
  154. Jackson ML, **Jackson LA**, Kieke B, et al. Incidence of medically attended influenza infection and cases averted by vaccination, 2011/12 and 2012/13 influenza seasons. *Vaccine* 2015;33:5181-7.
  155. Benoit A, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, McElhaney JE, Oostvogels L, van Essen GA, Gaglani M, **Jackson LA**, Vesikari T, Legrand C, Tibaldi F, Innis BL, Dewé W. Hemagglutination inhibition antibody titers as a correlate of protection against seasonal A/H3N2 influenza disease. *Open Forum Infect Dis* 2015;2.
  156. Frey SE, Wald A, Edupuganti S, **Jackson LA**, et al. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects. *Vaccine* 2015;33:5225-34.
  157. Sukumaran L, McCarthy NL, Li R, et al. Demographic characteristics of members of the Vaccine Safety Datalink (VSD): a comparison with the United States population. *Vaccine* 2015;33:4446-50.
  158. Schmoele-Thoma B, **Jackson LA**, Greenberg RN, et al. Immunogenicity of 13-valent pneumococcal conjugate vaccine in immunocompetent older adults with stable underlying medical conditions. *J Vaccines Immun* 2015;3:7-12.
  159. Chen WH, **Jackson LA**, Edwards KM, et al. Persistence of antibody to influenza A/H5N1 virus vaccine when co-administered with AS03 adjuvant. *Clin Vaccine Immunol* 2015;23:73-7.
- 2016**
160. Flannery B, Zimmerman RK, Gubareva LV, et al. Enhanced genetic characterization of influenza A(H3N2) viruses and vaccine effectiveness by genetic group, 2014-2015. *J Infect Dis* 2016;214:1010-9.
  161. Gaglani M, Pruszynski J, Murthy K, et al. Influenza vaccine effectiveness against the 2009 pandemic influenza A(H1N1) virus differed by vaccine type during 2013-2014 in the United States. *J Infect Dis* 2016;213:1546-56.
  162. Chung JR, Flannery B, Thompson MG, et al. Seasonal effectiveness of live attenuated and inactivated influenza vaccine. *Pediatrics* 2016;137:1-10.
  163. Naleway AL, Crane B, Smith N, et al. Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011. *Vaccine* 2016;34:167-71.
  164. Groom HC, Henninger ML, Smith N, et al. Influenza vaccination during pregnancy: influenza seasons 2002 through 2012, Vaccine Safety Datalink. *Am J Prev Med* 2016;50:480-8.
  165. McNeil MM, Weintraub ES, Duffy J, et al. Risk of anaphylaxis after vaccination in children and adults. *J Allergy Clin Immunology* 2016;137:868-78.
  166. Jackson ML, Bellamy A, Wolff M, Hill H, **Jackson LA**. Low-dose aspirin does not diminish the immune response to monovalent H1N1 vaccine in older adults. *Epidemiol Infect* 2016;144:768-71.
  167. Thompson MG, Clippard J, Petrie JG, et al. Influenza vaccine effectiveness for fully and partially vaccinated children 6 months to 8 years old during 2011-2012 and 2012-2013: the importance of two priming doses. *Pediatr Infect Dis* 2016;35:299-308.
  168. Duffy J, Weintraub E, Donahue D, et al. Febrile seizure risk after vaccination in children 6 to 23 months. *Pediatrics* 2016;138.
  169. Zimmerman RK, Nowalk MP, Chung J, et al. 2014-2015 influenza vaccine effectiveness in the United States by vaccine type. *Clin Infect Dis* 2016;63:1564-73.

170. Zimmerman RK, Balasubramani GK, Nowalk MP, et al. Classification and regression tree (CART) analysis to predict influenza in primary care patients. *BMC Infect Dis* 2016;16:503.

**2017**

171. **Jackson LA**, Frey SE, El Sahly HM, et al. Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery. *Vaccine* 2017;35:1675-82.
172. Klein NP, Lewis E, McDonald J, et al. Risk factors and familial clustering for fever 7-10 days after the first dose of measles vaccines. *Vaccine* 2017;35:1615-21
173. Donahue JG, Kieke BA, King JP, et al. Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010-11 and 2011-12. *Vaccine* 2017;35:5314-22.
174. Jackson ML, Chung JR, **Jackson LA**, et al. Influenza vaccine effectiveness during the 2015-2016 season. *N Engl J Med* 2017;377:534-43.
175. Duffy J, Lewis M, Harrington T, et al. Live attenuated influenza vaccine use and safety in children and adults with asthma. *Ann Allergy Asthma Immunol* 2017;118:439-44.
176. Storms AD, Chen J, **Jackson LA**, et al. Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults. *BMC Pulm Med* 2017;17:208.
177. Duffy J, Hambidge S, **Jackson LA**, et al. Febrile seizure risk after vaccination in children one to five months of age. *Pediatr Neurol* 2017;76:72-8.

**2018**

178. Sukumaran L, et al. Infant mortality and hospitalizations following maternal vaccination. *Pediatrics* 2018;141.
179. Stewart RJ, Flannery B, Chung JR, et al. Influenza antiviral prescribing for outpatients with an acute respiratory illness and at high risk for influenza-associated complications during five influenza seasons – United States, 2011-2016. *Clin Infect Dis* 2018;66:1035-41.
180. Jackson ML, Phillips CH, Benoit J, et al. Burden of medically attended influenza infection and cases averted by vaccination – United States, 2013/14 through 2015/16 influenza seasons. *Vaccine* 2018;36:467-72.
181. Jackson ML, Phillips CH, Benoit J, Madziwa L, Mackoff S, **Jackson LA**. The impact of selection bias on vaccine effectiveness estimates from test-negative studies. *Vaccine* 2018;36:751-7.
182. **Jackson LA**, Brady R, El Sahly HM, et al. Randomized clinical trial of single versus double dose of 13-valent pneumococcal vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. *Vaccine* 2018;36:606-14.
183. Zerbo O, Modaresi S, Goddard K, et al. Vaccination patterns in children after autism spectrum disorder diagnosis and in their younger siblings. *JAMA Pediatr* 2018;72:469-475.
184. Russell K, Chung JR, Monto AS, et al. Influenza vaccine effectiveness in older adults compared with younger adults over five seasons. *Vaccine* 2018;36:1272-8.
185. Flannery B, Smith C, Garten RJ, et al. Influence of birth cohort on effectiveness of 2015-2016 influenza vaccine against medically attended illness due to 2009 pandemic influenza A(H1N1) virus in the United States. *J Infect Dis* 2018;218:189-196.
186. Widdice LE, Unger ER, Berry A, et al. Antibody responses among adolescent females receiving two or three quadrivalent HPV vaccine doses at standard and prolonged intervals. *Vaccine* 2018;36:881-9.
187. **Jackson LA**, Rupp R, Papadimitriou A, Wallace D, Raanan M, Moss KJ. A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate. *Vaccine* 2018;36:3976-3983.

188. Jackson ML, Yu O, Nelson JC, et al. Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents. *Pharmacoepepi Drug Safety* 2018;27:921-925.
189. Kuntz J, Crane B, Weinmann S, Naleway AL for the Vaccine Safety Datalink Investigator Team. Myocarditis and pericarditis are rare following live viral vaccinations in adults. *Vaccine* 2018;36:1524-7.
190. Tseng HF, Sy LS, Qian L, et al. Pneumococcal conjugate vaccine safety in elderly adults. *Open Forum Infect Dis* 2018;5:ofy100.
191. Brady RC, **Jackson LA**, Frey SE, Shane AL, Walter EB, Swamy GK, Schlaudecker EP, Szefer E, Wolff M, McNeal MM, Bernstein DI, Steinhoff MC. Randomized trial comparing the safety and antibody responses to live attenuated versus inactivated influenza vaccine when administered to breastfeeding women. *Vaccine*. 2018;36(31):4663-4671. doi: 10.1016.
192. Groom HC, Irving SA, Koppolu P, Smith N, Vazquez-Benitez G, Kharbanda EO, Daley MF, Donahue JG, Getahun D, **Jackson LA**, Tse Kawai A, Klein NP, McCarthy NL, Nordin JD, Sukumaran L, Naleway AL. Uptake and safety of Hepatitis B vaccination during pregnancy: A Vaccine Safety Datalink study. *Vaccine* 2018;36:6111-6116.
193. Stewart RJ, Flannery B, Chung JR, Gaglani M, Reis M, Zimmerman RK, Nowalk MP, **Jackson L**, Jackson ML, Monto AS, Martin ET, Belongia EA, McLean HQ, Fry AM, Havers FP. Influenza Antiviral Prescribing for Outpatients With an Acute Respiratory Illness and at High Risk for Influenza-Associated Complications During 5 Influenza Seasons-United States, 2011-2016. *Clin Infect Dis*. 2018;66(7):1035-1041. doi: 10.1093/cid/cix922.
194. Shang M, Chung JR, Jackson ML, **Jackson LA**, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Fry AM, Flannery B. Influenza vaccine effectiveness among patients with high-risk medical conditions in the United States, 2012-2016. *Vaccine* 2018;36:8047-8053.
195. Munoz FM, **Jackson LA**, Swamy GK, Edwards KM, Frey SE, Stephens I, Ault K, Winokur P, Petrie CR, Wolff M, Patel SM, Keitel WA. Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women. *Vaccine* 2018;36:8054-8061.
196. Havers FP, Hicks LA, Chung JR, et al. Outpatient antibiotic prescribing for acute respiratory infections during influenza seasons. *JAMA Netw Open* 2018;1:e180243.
- 2019**
197. Flannery B, Chung JR, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, **Jackson LA**, Rolfes MA, Spencer S, Fry AM. Influenza Vaccine Effectiveness in the United States during the 2016-2017 Season. *Clin Infect Dis*. 2019;68:1798-1806.
198. Havers FP, Chung JR, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, **Jackson LA**, Monto AS, Petrie JG, Fry AM, Flannery B. Influenza vaccine effectiveness and statin use among adults in the United States, 2011-2017. *Clin Infect Dis* 2019;68:1616-22.
199. Appiah GD, Chung JR, Flannery B, Havers F, Zimmerman RK, Nowalk MP, Monto AS, Martin ET, Gaglani M, Murthy K, **Jackson LA**, Jackson ML, McLean HQ, Belongia EA, Fry AM. Hospitalization following outpatient medical care for influenza: US Influenza Vaccine Effectiveness Network, 2011-2016. *Influenza Other Respir Viruses* 2019;13:133-137.
200. McClure DL, Jacobsen SJ, Klein NP, Naleway AL, Kharbanda EO, Glanz JM, Jackson LA, Weintraub ES, McLean HQ. Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders. *Vaccine* 2019;37:76-79.
201. Keitel WA, Voronca DC, Atmar RL, et al. Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: a meta-analysis. *Vaccine* 2019;37:5535-5543.

202. Zheng C, Yu W, Xie F, et al. The use of natural language processing to identify Tdap-related local reactions at five healthcare systems in the Vaccine Safety Datalink. *Int J Med Inform* 2019;127:27-34.
203. Groom HC, Smith N, Irving SA, et al. Uptake and safety of hepatitis A vaccination during pregnancy: a Vaccine Safety Datalink study. *Vaccine* 2019;37:6648-6655.
204. Donahue JG, Kieke BA, King JP, et al. Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012-13, 2013-14, and 2014-15. *Vaccine* 2019;37:6673-6681.
205. Abate G, et al. Variability in the Management of Adults with Pulmonary Nontuberculous Mycobacterial Disease. *Clin Infect Dis* 2020;ciaa252. Online ahead of print.
206. Donahue JG, Kieke BA, Lewis EM, et al. Near real-time surveillance to assess the safety of the 9-valent human papillomavirus vaccine. *Pediatrics* 2019;144.
207. Cook AJ, Wellman RD, Marsh T, et al. Applying sequential surveillance methods that use regression adjustment or weighting to control confounding in a multisite, rare-event, distributed setting: Part 2 in-depth example of a reanalysis of the measles-mump-rubella-varicella combination vaccine and seizure risk. *J Clin Epidemiol* 2019;113:114-122.
208. Rolfes MA, Flannery B, Chung JR, et al. Effects of influenza vaccination in the United States during the 2017-2018 influenza season. *Clin Infect Dis* 2019;69:1845-1853.

**2020**

209. Anderson EJ, Lai L, Wrammert J, et al. Plasmablast, memory B cell, CD4+ T cell, and circulating follicular helper T cell responses to a non-replicating modified vaccinia Ankara vaccine. *Vaccines (Basel)* 2020;8:69.
210. Ahmed F, Kim S, Nowalk MP, et al. Paid leave benefits and access to telework as determinants of work attendance during medically attended acute respiratory illness: US Influenza Vaccine Effectiveness Network, 2017-2018. *Emerg Infect Dis* 2020;26.
211. Flannery B, Garten Kondor RJ, Chung JR, et al. Spread of antigenically drifted influenza A (H3N2) viruses and vaccine effectiveness in the United States during the 2018-2019 season. *J Infect Dis* 2020;221:8-15.
212. Munoz FM, Patel SM, Jackson LA, et al. Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants. *Vaccine*. 2020;38(33):5355-5363.
213. Hesse EM, Navarro RA, Daley MF, et al. Risk for subdeltoid bursitis after influenza vaccination: a population-based cohort study. *Ann Intern Med* 2020;173:253-261. Doi: 10.7326/M19-3176.
214. Kim SS, Flannery B, Foppa IM, et al. Effects of prior season vaccination on current season vaccine effectiveness in the US Flu VE Network, 2012-13 through 2017-18. *Clin Infect Dis*. 2020;ciaa706. Online ahead of print.
215. Tenforde MW, Chung J, Smith ER, et al. Influenza vaccine effectiveness in inpatient and outpatient settings in the United States, 2015 - 2018 [published online ahead of print, 2020 Apr 9]. *Clin Infect Dis*. 2020;ciaa407. doi:10.1093/cid/ciaa407
216. Gaglani M, et al. Effectiveness of trivalent and quadrivalent inactivated vaccines against influenza B in the United States, 2011-2012 to 2016-2017. *Clin Infect Dis* 2020;ciaa102.
217. Chung JR, Flannery B, Gaglani M, et al. Patterns of influenza vaccination and vaccine effectiveness among young US children who receive outpatient care for acute respiratory tract illness. *JAMA Pediatr*. 2020;174(7):705-713. doi:10.1001/jamapediatrics.2020.0372
218. Ahmed F, Kim S, Nowalk MP, et al. Paid Leave and Access to Telework as Work Attendance Determinants during Acute Respiratory Illness, United States, 2017-2018. *Emerg Infect Dis*. 2020;26(1):26-33. doi:10.3201/eid2601.190743
219. Yu W, Zheng C, Xie F, et al. The use of natural language processing to identify vaccine-related anaphylaxis at five health care systems in the Vaccine Safety Datalink. *Pharmacoepidemiol Drug Saf* 2020;29:182-188.

220. Jackson LA, Anderson EJ, Roupheal NG, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. *N Engl J Med* 2020;383:1920-1931. doi:10.1056/NEJMoa2022483.
221. Tenforde MW, Kondor RJG, Chung JR, et al. Effect of antigenic drift on influenza vaccine effectiveness in the United States – 2019-2020. *Clin Infect Dis* 2020. Online ahead of print. doi:10.1093/cid/ciaa1884.
222. Balasubramani GK, Choi WS, Nowalk MP, et al. Relative effectiveness of high dose versus standard dose influenza vaccines in older adult outpatients over four seasons, 2015-16 to 2018-19. *Vaccine*. 2020;38(42):6562-6569. doi:10.1016/j.vaccine.2020.08.011
223. Anderson EJ, Roupheal NG, Widge AT, et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. *N Engl J Med*. 2020;383:2427-2438. doi:10.1056/NEJMoa2028436
224. Kharbanda EO, Vazquez-Benitez G, DeSilva MB, et al. Developing algorithms for identifying major structural birth defects using automated electronic health data. *Pharmacoepidemiol Drug Saf* 2021;30:266-274. doi: 10.1002/pds.5177
225. Chung JR, Rolfes MA, Flannery B, et al. Effects of influenza vaccination in the United States during the 2018-2019 influenza season. *Clin Infect Dis* 2020;71:e368-e376. doi: 10.1093/cid/ciz1244.
226. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med* 2020. doi: 10.1056/NEJMoa2035389.
227. Abate G, Stapleton JT, Roupheal N, et al. Variability in the management of adults with pulmonary nontuberculous mycobacterial disease. *Clin Infect Dis* 2020. doi: 10.1093/cid/ciaa252.

## 2021

228. Widge AT, Roupheal NG, Jackson LA, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. *N Engl J Med* 2021;384:80-82. doi: 10.1056/NEJMc2032195.
229. Kharbanda EO, Vazquez-Benitez G, DeSilva MB, et al. Developing algorithms for identifying major structural birth defects using automated electronic health data. *Pharmacoepidemiol Drug Saf* 2021;30:266-274. doi: 10.1002/pds.5177

## Book Chapters

1. **Jackson LA**, Grayston JT. *Chlamydia pneumoniae* (TWAR). In: Schlossberg D, ed. *Current Therapy of Infectious Disease*. St. Louis: Mosby -Year Book, Inc., 1996:398-399.
2. **Jackson LA**, Grayston JT. *Chlamydia*. In: Bittar EE, Bittar N (eds). *Principles of Medical Biology*, Vol 9A. Greenwich, CT: JAI Press Inc, 1997:319-328.
3. **Jackson LA**, Grayston JT. *Chlamydia pneumoniae*. In: Yu VL, Merigan TC Jr, Barriere, eds. *Antimicrobial Therapy and Vaccines*. Baltimore: Williams & Wilkins, 1999:583-586.
4. **Jackson LA**, Marcuse EK. Measles. In: Burg FD, Ingelfinger JR, Wald ER, Polin RA, eds. *Current Pediatric Therapy*, Vol 16. Philadelphia: W.B. Saunders Company, 1999:123-6.
5. **Jackson LA**. Trench fever. In: Strickland GT, ed. *Hunter's Tropical Medicine*, 8<sup>th</sup> ed. Philadelphia: W.B. Saunders Company, 2000:442-3.
6. **Jackson LA**, Grayston JT. *Chlamydia pneumoniae*. In: Mandell GL, Bennett JE, Dolin R, eds. *Principles and Practice of Infectious Diseases*, 5<sup>th</sup> edition, 2000:2007-2014.
7. **Jackson LA**, Grayston JT. *Chlamydia pneumoniae* (TWAR). In: Schlossberg D, ed. *Current Therapy of Infectious Disease*. 2<sup>nd</sup> ed. St. Louis: Mosby -Year Book, Inc., 2001:481-483.
8. **Jackson LA**, Grayston JT. *Chlamydia pneumoniae*. In: Yu VL, Merigan TC Jr, Barriere, eds. *Antimicrobial Therapy and Vaccines*. 2<sup>nd</sup> ed. Baltimore: Williams & Wilkins, 2002:933-938.
9. **Jackson LA**. *Chlamydia (Chlamydia) pneumoniae*. In: Mandell GL, Bennett JE, Dolin R, eds. *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*, 6<sup>th</sup> edition, 2005:2258-2268.

10. **Jackson LA**, Neuzil KM. *Pneumococcal polysaccharide vaccines*. In: Plotkin SA, Orenstein WA, Offit PA, eds. *Vaccines*, 5<sup>th</sup> edition, 2008:569-604.
11. **Jackson LA**, Siber G. *Immunogenicity and safety in adults*. In: Käyhty H, Siber G, eds. *Pneumococcal conjugate vaccines*, 1<sup>st</sup> edition, 2008:245-260.
12. Schuchat A, **Jackson LA**. *Immunization Principles and Vaccine Use*. In: Longo, DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, eds. *Harrison's Principles of Internal Medicine*, 18<sup>th</sup> edition, 2012:1031-41.
13. **Jackson LA**. *Pneumococcal polysaccharide vaccines*. In: Plotkin SA, Orenstein WA, Offit PA, eds. *Vaccines*, 6<sup>th</sup> edition, 2013:542-572.
14. Schuchat A, **Jackson LA**. *Immunization Principles and Vaccine Use*. In: Kasper D, Fauci AS, Hauser SL, Longo D, Jameson JL, Loscalzo J, eds. *Harrison's Principles of Internal Medicine*, 19<sup>th</sup> edition, 2015.

### **Other Published Scholarly Papers**

1. **Jackson LA**, Wenger JD and the Meningococcal Disease Study Group. Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989-1991. *CDC Surveillance Summaries*, June 4, 1993. *MMWR* 1993;42:(No. SS-2):21-30.
2. **Jackson LA**, Grayston JT. Chlamydia pneumoniae and Mycoplasma pneumoniae infections. *Curr Opin Infect Dis* 1996;9:89-93.
3. **Jackson LA**. Prevention of meningococcal disease. *J Irish Coll Physicians Surgeons* 1997;26:42-5.
4. Perkins BA, **Jackson LA**, Schillinger JA, Wenger JD. Control and prevention of serogroup C meningococcal disease: Evaluation and management of suspected outbreaks: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 1997;46 (RR-5):13-22.
5. Spach DH, **Jackson LA**. Bacterial meningitis. *Neurol Clin* 1999 Nov;17(4):711-735.
6. Starr JR, **Jackson LA**. Chlamydia pneumoniae and atherosclerotic cardiovascular disease. *Clin Microbiol Newsletter* 2000;21:145-148.
7. Chen RT, DeStefano F, Davis RL, **Jackson LA**, et al. The Vaccine Safety Datalink: Immunization Research in United States Health Maintenance Organizations. *Bull World Health Organ*. 2000;78(2):186-94.

### **Editorials**

1. Jackson LA. Infections and atherosclerotic cardiovascular disease. *Infect in Medicine* 1998;15:480.
2. Jackson LA. Evaluating diabetes mellitus as a risk factor for community-acquired infections. *Clinical Infectious Diseases* 2005;41:289-90.
3. Jackson LA. The benefits of examining influenza vaccine associations outside of influenza season. *Amer J Resp Critical Care Medicine* 2008;178:439-440.
4. Jackson LA. Using surveillance to evaluate influenza vaccine effectiveness. *J Infect Dis* 2008;199:155-8.

### **Letters to the Editor**

1. Schwartz B, **Jackson LA**. Invasive group B streptococcal disease in adults. *JAMA* 1991;266:3284.
2. **Jackson LA**, Schuchat A. Reporting of toxic shock syndrome. *J Infect Dis* 1992;166:445.
3. Perkins BA, Swaminathan B, **Jackson LA**, et al. Case 22-1992—pathogenesis of cat scratch disease. *N Engl J Med* 1992;327:1599-1560.
4. **Jackson LA**, Farley MM, Schuchat A. Adult group B streptococcal disease. *Ann Intern Med* 1996;125:152-3.

5. **Jackson LA**, Campbell LA, Kuo C-C, Grayston JT. Detection of *Chlamydia pneumoniae* in atherectomy specimens. *J Infect Dis* 1996;174:893-4.
6. **Jackson LA**, Neuzil KM, Thompson WW. Pneumococcal vaccination in older adults. *NEJM* 2003;349:713-714.
7. **Jackson LA**, Jackson ML, Weiss NS. Bias in studies of influenza vaccine effectiveness: the authors reply to Hak et al. *Int J Epidemiol* 2006;35:799-800.
8. Jackson ML, Weiss NS, Nelson JL, **Jackson LA**. Bias in the association of influenza vaccination and pneumonia mortality. *Arch Intern Med* 2007;167:1553-53.
9. Nelson JC, Jackson ML, **Jackson LA**. Effectiveness of influenza vaccination. *N Engl J Med* 2007;375:2728-9.
10. Simonsen L, Taylor RJ, Viboud C, Miller MA, **Jackson LA**. More on influenza vaccine benefits in seniors. *Lancet Infect Dis* 2008;8:463-465.
11. **Jackson LA**, Nelson JC. Statins and mortality. *J Infect Dis* 2012;206:303-4.
12. Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, **Jackson LA**. Cost effectiveness of adult pneumococcal vaccination: response to Grabenstein et al. *Vaccine* 2013;31:2109.
13. Osterholm MT, Kelley NS, Belongia EA, **Jackson LA**, Jackson ML. Reply: Letter to the editor, Cochrane rearranged. *Vaccine* 2015;33:12.
14. Chung JR, Flannery B, Zimmerman RK, et al. Prior-season vaccination and risk of influenza during the 2014-2015 season in the United States. *J Infect Dis* 2017;216:284-5.

#### **Manuscripts Submitted or in Preparation**

1. Swamy GK, Patel SM, **Jackson LA**, Edwards K, Frey S, Kotloff KL, Noah DL, Hill H, Petrie CR, Wolff M. Safety and immunogenicity of the 2009 pandemic H1N1 influenza vaccine in pregnancy.
2. Shinde V, Piedra PA, Belongia EA, et al. A tale of two trials: respiratory syncytial virus (RSV) F vaccine for prevention of RSV in older adults.
3. El Sahly HM, Atmar RL, Patel SM, et al. Safety and immunogenicity of heterologous prime-boost influenza A/H7N7-H7N9 vaccination.
4. Winokur P, El Sahly HM, Mulligan M, et al. Immunogenicity and safety of different dose intervals and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults 65 years and older.
5. Kharbanda EO, Vazquez-Benitez G, DeSilva M, et al. Risks for spontaneous abortion and adverse birth outcomes following inadvertent 9-valent human papillomavirus vaccination in pregnancy.
6. Duffy J, Iqbal S, McEvoy CE, et al. Narcolepsy incidence in seven United States health care systems, 2007-2012.
7. Glanz JM, Clarke CL, Daley MF, et al. The association between the recommended childhood vaccination schedule and type 1 diabetes mellitus in children.
8. Naleway AL, Crane B, Irving SA, et al. Vaccine safety datalink infrastructure enhancements for evaluating the safety of maternal vaccination.
9. Chung JR, Flannery B, Kim SS, et al. Publishing interim early or mid-season influenza vaccination effectiveness – US Flu VE Network.
10. Murphy SC, Deye GA, Sim BKL, et al. PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: a randomized, placebo-controlled trial with controlled human malaria infection.

### **NIH/CDC SPECIAL EMPHASIS GRANT REVIEW PANELS**

Screening for STDs in Managed Care. CDC, 1997.

International Collaborations in Infectious Disease Research (ICIDR) and Actions for Building Capacity in Support of ICIDR Program. NIAID, NIH, 1999.

Oral Biology and Medicine Study Section, ad hoc reviewer, NIH, 2000.

Vaccine Treatment and Evaluation Unit Contract Review Panel, NIAID, NIH, 2001.

Role of Infectious Agents in Vascular Disease, NHLBI, NIH, 2002.

Development and testing of a Modified Vaccinia Ankara (MVA) vaccine. NIAID, NIH, 2002.

Review of Training Grant Applications, Microbiology and Infectious Diseases Review Committee, NIH, February 2006.

Special Emphasis Panel/Scientific Review Group 2006/05 AIDS, March 2006 and November 2006

NIAID Clinical Trials Planning Grants Special Emphasis Panel, February 2008.

Influenza Vaccine Effectiveness Special Emphasis Panel, CDC, May 2008.

Addressing Emerging Infectious Diseases in the Republic of India Special Emphasis Panel, CDC, June 2008.

Strengthening Infectious Disease Research Capacity for Public Health Action in Guatemala and Central America Special Emphasis Panel, CDC, April 2009.

NIH Challenge Grant reviewer, June 2009

CISA expert review panel, CDC, 2011

Expert review panel, Emerging Infections Program, CDC, 2012

NIAID HIV Network Clinical Site Special Emphasis Panel, April 2020.

### **EDITORIAL BOARD**

Editorial Advisory Board, Journal of Infectious Diseases, 2006-2011

### **DATA SAFETY MONITORING BOARDS**

Appointed member, DSMB for a CDC-sponsored clinical trial to evaluate the safety and immunogenicity of anthrax vaccine in civilians, 2001-2007.

Appointed member, DSMB for a FDA licensure trial of influenza vaccine in ambulatory elderly adults sponsored by Protein Sciences Corporation, 2006-2007

Appointed member, DSMB for licensure trial of a whole cell pneumococcal vaccine in adults sponsored by PATH, 2012.

Appointed member, DSMB for licensure trial of a whole cell pneumococcal vaccine in adults and children sponsored by PATH, 2013.

Appointed member, DSMB for licensure trial of a live attenuated H2N2 influenza vaccine sponsored by PATH, 2013.

#### **FEDERAL ADVISORY COMMITTEES**

Member, FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC), 2006-2010

Member, National Vaccine Advisory Committee (NVAC), 2008-2012

#### **OTHER NATIONAL OR INTERNATIONAL COMMITTEES**

Member, Advisory Committee on Immunization Practices (ACIP) pneumococcal vaccine working group, 2006-2012

Member, Advisory Committee on Immunization Practices (ACIP) RSV vaccine working group, 2016-

Member, World Health Organization working group on pneumococcal polysaccharide vaccine, 2007-2008

Member, Steering Committee for the National Quality Forum (NQF) project, National Voluntary Consensus Standards for Adult Immunizations, 2007-2008

Member, External Review Panel, Institute of Medicine review of a draft letter report "Review of Priorities in the National Vaccine Plan", 2008.

Member, External Review Panel, Institute of Medicine Workshop Summary on "Achieving Sustainable Global Capacity for Surveillance and Response to Emerging Diseases of Zoonotic Origin," 2008

Member, Planning Committee, the Infectious Diseases Society of America – Association of Specialty Professors (ASP) Workshop on Immunization in Older Adults, 2008.

Member, External Review Panel, Institute of Medicine review of a draft report "Review of Priorities in the National Vaccine Plan", 2009.

Member, Research Oversight Committee, Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN), 2012-

## ACTIVE FUNDING

3UM1 AI148373-S2 (Jackson L) 7/22/2020-11/30/2022 YR 2: 0.03 Calendar  
National Institute of Allergy and Infectious Diseases \$3,441,912 Total Costs Yr 2

**Vaccine and Treatment Evaluation Units (VTEUs) Site Preparedness Funds, additional Protocol 20-0003 funds, and CoVPN Trial Implementation Funds**

To prepare for large scale COVID-19 vaccine trials, to implement the trial “A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older” and to enroll additional subjects included in trial titled “Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults.”

3UM1 AI148373-S1 (Jackson L) 2/24/2020-11/30/2022 YR 2: 1.20 Calendar  
National Institute of Allergy and Infectious Diseases \$371,738 Total Costs Yr 2

**Vaccine and Treatment Evaluation Units (VTEUs) Protocol 20-0003 and Vaccine Registry**

To design and conduct the protocol titled “Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults.

UM1 AI148373 (Jackson L) 12/1/2019-11/30/2026 YR 2: 3.60 Calendar  
National Institute of Allergy and Infectious Diseases \$658,947 Total Costs Yr 2

**Vaccine and Treatment Evaluation Units (VTEUs)**

This proposal is in response to a new VTEU structure which will involve greater collaboration between the VTEUs, NIAID, and the newly formed Leadership Group structure that are all part of the NIAID Infectious Diseases Clinical Research Consortium (IDCRC). Under the new cooperative agreement, the Kaiser Washington VTEU will continue to conduct clinical research and trials, including trials conducted under an IND or IDE, within the Kaiser Washington integrated care system to contribute to the priority research foci of NIAID.

75N93019F00131-FY.2020.A1B1C1D1.0123 (Jackson L) 7/12/2020-7/11/2021 YR 1: 0.60 Calendar  
National Institute of Allergy and Infectious Diseases \$148,927 Total Costs

**Vaccine and Treatment Evaluation Units (VTEUs) Core**

To design and conduct Phase 1, Phase 2, Phase 3 and Phase 4 clinical trials and clinical studies of candidate vaccines and therapeutics, as well as conduct other evaluations and analyses for vaccines against infectious diseases.

HHSN27200007 (Jackson L) 9/17/2017-12/31/2020 YR 3: 0.25 Calendar  
National Institute of Allergy and Infectious Diseases \$1,248,287 Total Costs

**Vaccine and Treatment Evaluation Units (VTEUs) Protocol 11-0042**

To design and conduct the protocol titled “A Phase 1 Dose Escalation Trial to Assess the Safety and Efficacy of Infectious (Replication-intact), Cryopreserved Plasmodium falciparum Sporozoites (PfSPZ Challenge) administered by Direct Venous Inoculation under Chloroquine Cover (PfSPZ-CVac) on Varying Schedules in Healthy Malaria-Naïve Adults in the United States”.

HHSN27200005-14-0088.B1C1D1.0030 (Jackson L) 7/12/17-12/31/2020 YR 3: 0.50 Calendar  
National Institute of Allergy and Infectious Diseases \$2,467,100 Total Costs

**Vaccine and Treatment Evaluation Units (VTEUs) Protocol 14-0088**

To design and conduct the protocol titled “A Phase 1, Two Arm, Open Label Trial to Evaluate the Safety, Immunogenicity and Preliminary Efficacy of Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum Parasites (GAP3KO) administered via the Bite of Infected Anopheles stephensi Mosquitoes to Malaria-Naïve Adults Living in the United States”.

HHSN27200009-FY.2017.B8C12.0080 (Jackson L) 7/28/17-12/31/2020 YR 3: 0.50 Calendar  
National Institute of Allergy and Infectious Diseases \$2,680,772 Total Costs  
**Vaccine and Treatment Evaluation Units (VTEUs) Protocols 17-0075, 17-0076, 17-0090**  
To design and conduct three Phase II studies of H7N9 Inactivated Influenza Vaccine.

200-2012-53421 (Jackson L) 9/20/2012-9/19/2022 YR 3: 2.76 Calendar  
Centers for Disease Control and Prevention \$3,836,026 Total Costs all years  
**Vaccine Safety Datalink (VSD) Project**  
This long-term (1991-present) multi-site CDC-sponsored project uses aggregate information from the populations of eight managed care organizations (MCOs) in the United States to conduct prospective and retrospective assessments of vaccine safety, vaccine efficacy, and the epidemiology of vaccine preventable diseases among children and adults. Data sources include MCO administrative databases, medical records, and participant survey data.

U01 IP001037 (Jackson M) 8/1/2016-7/30/2021 YR 4: 0.60 Calendar  
Centers for Disease Control and Prevention \$4,590,003 Total Costs all years  
**Prospective Annual Estimates of Influenza Vaccine Effectiveness and Burden of Disease**  
This multi-site CDC-sponsored project involves, at the Kaiser Washington site, identifying Kaiser members seeking care for an acute respiratory illness at a Kaiser clinic, enrolling eligible children and adults, collecting respiratory specimens for PCR testing to identify persons with influenza infection, and identifying influenza vaccine status using Kaiser data systems. The data obtained across the network are used to conduct test negative design analyses to estimate the effectiveness of the current season's influenza vaccines. The results of interim analyses are reported in February to provide information to guide public health policy and final end-of-season results are reported in published manuscripts.